GPCR-BSD: a database of binding sites of human G-protein coupled receptors under diverse states Fan Liu , Han Zhou , Xiaonong Li , Liangliang Zhou , Chungong Yu , Haicang Zhang , Dongbo Bu 🤩 Seriously, why would

.; Han, G. W.; Wu, Y.; Zhao, S.; Shui, W.; Li, S.; Korde, A.; Laprairie, R. B.; Stahl, E. L.; Ho, J. -H.; Zvonok, N.; Zhou, H.; Kufareva, I.; Wu, B.; Zhao, Q.; Hanson, M. A.; Bohn, L. -H.; Wu, Y.; Wu, L.; Popov, P.; Benchama, O.; Zvonok, N.; Locke, K.; Qu, L.; Han, G. W.; Iyer, M.

6P4]CCL5), a chemokine antagonist ([5P7]CCL5), and a small-molecule inverse agonist (maraviroc) (Tan, Zhu et al. 2013, Zheng, Han et al. 2017, Isaikina, Tsai et al. 2021, Zhang, Chen et al. 2021). its constitutive activity (Yen, Schafer et al. 2022) which is also supported by mutagenesis studies (Han

disruption of natural spatial and temporal signaling patterns regulated by physiological systems (Wold and Zhou intervention for metabolic diseases such as liver disease, obesity and diabetes (Secor et al. 2021; Wold and Zhou

Jianming Han, Tao Che for their analysis of GPCR-G protein selectivity revealed by structural pharmacology

Wager TT, Hou X, Verhoest PR, Villalobos A. Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, et al.

Zhou, Y., et al., Multiple GPCR Functional Assays Based on Resonance Energy Transfer Sensors. 

therapeutic intervention for metabolic diseases such as liver disease, obesity and diabetes (Wold and Zhou

Week’s Highlights: SNX9 family mediates βarrestin-independent GPCR endocytosis Valeria Robleto , Ya Zhuo

immunosuppressive tumor microenvironment, and facilitate metastatic spread (Nagarsheth, Wicha, and Zou

Qian, Y., Ma, Z., Liu, C., Li, X., Zhu, X., Wang, N., Xu, Z., Xia, R., Liang, J., Duan, Y., Yin, H.,